Resource data sheet
DNA Bank Top
Please review the HTS results indicated by check icon below as well as clone information before placing your order.

CSII-BNRF1-HA (#RDB20444)

Lentivirus vector plasmid of Epstein-Barr virus BNRF1. HA-tag at C-terminus.

Clone info. Lentivirus vector plasmid of Epstein-Barr virus BNRF1. HA-tag at C-terminus. See Sagou et al., Plos Pathog, 20: e1011954, 2024 (DOI: doi: 10.1371/journal.ppat.1011954).
Vector backbone CSII-CMV-MCS-IRES2-Bsd (RDB04385) (plasmid)
Selectable markers Ampicillin (E. coli), Blasticidin S (mammalian cell).
Growth conditions LB+Ampicillin, 37oC
Gene/insert name Epstein-Barr virus BNRF1 cDNA, synthetic HA-tag.
Depositor|Developer Sato, Yoshitaka |
 
Sequence (full) RDB20444hts01.seq checkAssembled from experimentally sequenced data.
Publication Sagou, K., PLoS Pathog. 2024 Feb 1;20(2):e1011954 (2024). PMID 38300891. [link to RRC of NBRP]
Test sheet RDB20444C0p1-1.pdf 
 

Distribution information

Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
Ordering forms
Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ]
MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ]
Approval form by depositor [Word]
Please visit Ordering instruction.[link] 
Terms and conditions for distribution In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested. (Sagou, Plos Pathogens, 20(2): e1011954, 2024) Prior to requesting the BIOLOGICAL RESOURCE, the RECIPIENT shall obtain approval from the DEPOSITOR using the Approval Form. For use of the BIOLOGICAL RESOURCE by a for-profit organization, the RECIPIENT shall reach an agreement with the DEPOSITOR on terms and conditions of use of the BIOLOGICAL RESOURCE and shall obtain a prior written consent from the DEPOSITOR. The RECIPIENT shall contact the DEPOSITOR in the case of application for any patents or commercial use based on the results from the use of the BIOLOGICAL RESOURCE.
Additional terms and conditions:
Regarding lentivirus vector: The RECIPIENT agrees to expressly describe Dr. Hiroyuki Miyoshi as the Developer of the lentivirus vector. The availability of the BIOLOGICAL RESOURCE is limited to a RECIPIENT of a not-for profit institution for a not-for-profit academic purpose.
Remarks Remember that you will be working with samples containing infectious virus.
Please obtain written approval of the depositor.
提供案内 (日本国内) [open/close]

必要書類
提供依頼書  [依頼書の記入例 ]
提供同意書 (MTA, 非営利学術目的用)[Word] [MTAの記入例 ]
寄託者による提供承諾書 [Word]
手続きの概要は、「レンチウイルスベクターの提供申し込み」をご覧ください。
MTAに書く使用条件 利用者は、研究成果の公表にあたって寄託者の指定する文献を引用する(Sagou, Plos Pathogens, 20(2): e1011954, 2024)。利用者は提供承諾書を用いて、事前に寄託者の承諾を得る。営利機関又は商業目的利用の希望者は、事前に利用条件等につき寄託者と合意し、提供承諾を得ること。利用者が本件リソースを使用して得られた研究成果に基づき特許等の申請、及び事業活動を行う場合は、寄託者と別途協議を行う。　
付加的使用条件：
レンチウイルスベクターについて：本件研究材料を利用した研究結果等を発表する際は、レンチウイルスベクターが三好浩之博士により開発されたことを明示する。本件リソースの使用は学術機関での学術研究に限る。
備考 このリソースはウイルス粒子産生用のため、取扱いに注意が必要です。
寄託者の書面による提供承諾が必要です。

Catalog # Resource name Shipping form Fee (non-profit org.)
RDB20444 CSII-BNRF1-HA DNA solution JPY 9,460 (not-for-profit academic purpose)
plus cost of shipping containers, dry ice (if required) and shipping charge

Ordering instruction of plasmids [in Japanese] [in English]

How to cite this biological resource

Materials & Methods section:

The CSII-BNRF1-HA was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB20444).

Reference section:

Sagou, K., Sato, Y., Okuno, Y., Watanabe, T., Inagaki, T., Motooka, Y., Toyokuni, S., Murata, T., Kiyoi, H., Kimura, H., Epstein-Barr virus lytic gene BNRF1 promotes B-cell lymphomagenesis via IFI27 upregulation. PLoS Pathog. 2024 Feb 1;20(2):e1011954 (2024). PMID 38300891. [link to RRC of NBRP]

Further references such as user reports and related articles (go to bottom)

References

Original, user report and related articles

original Sagou, K., Epstein-Barr virus lytic gene BNRF1 promotes B-cell lymphomagenesis via IFI27 upregulation. PLoS Pathog. 2024 Feb 1;20(2):e1011954 (2024). PMID 38300891. [link to RRC of NBRP]